Findings of a record review suggest that even patients with anaphylaxis can be discharged after stabilization.
Patients with allergic reactions are often observed in the emergency department (ED) or hospital for 6 to 24 hours, even after stabilization. Investigators reviewed charts for visits for allergy or anaphylaxis at two Canadian EDs, to determine the incidence of clinically important biphasic reactions.
During the 5-year study period, there were 496 visits for anaphylaxis and 2323 for nonanaphylactic allergic reactions; in 54% and 21% of these visits, respectively, patients received epinephrine. Five clinically important biphasic reactions were identified: Two occurred in the anaphylaxis group (0.4%) during the ED visit, and three occurred in the allergic-reaction group (0.1%) between 1 and 6 days after discharge. There were no fatalities withi…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals